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Should Intravenous n-Acetylcysteine
Be Considered Standard of
Care for Prevention of
Radio-Contrast–Induced Nephropathy?
Baker et al. (1) in a recent issue of the Journal reported results from
the RAPPID trial, which tested the hypothesis that intravenous
(IV) administration of n-acetylcysteine (NAC) with saline was
superior to saline hydration alone for emergent procedures. The
investigators concluded that IV NAC should be considered for all
patients at risk for radiocontrast-induced nephropathy (RCIN)
when time precludes oral prophylaxis. Although this trial encour-
ages further research into the use of IV NAC for prevention of
RCIN, several questions must be answered before IV NAC should
be considered standard of care, particularly in the U.S.
Comparing a high-dose IV NAC regimen with hydration alone,
the researchers found that the risks of RCIN were decreased in
patients receiving IV NAC. These findings are similar to others
utilizing oral NAC prophylaxis, although in most cases the
regimen was initiated several hours prior to a planned procedure
(2–4). Data evaluating the use of oral NAC immediately prior to
a procedure are limited (4,5). Diaz-Sandoval et al. (4) compared
oral NAC with placebo in the APART trial, reporting significant
results favoring the oral NAC regimen. Durham et al. (5) did not
report benefits from oral NAC 1200 mg given 1 h prior to and 3 h
after a procedure when compared with placebo and hydration
alone. It is unclear whether the unique oral NAC regimen or the
volume of saline hydration used contributed to negative results.
Inclusion of an oral NAC regimen as a comparative arm in the
RAPPID trial would have been helpful in clarifying whether an IV
NAC regimen offers advantages over oral administration.
Intravenous NAC is not commercially available in the U.S., and
although some support the IV use of the inhalation solution for
acetaminophen overdose, such regimens are infrequently used in
the U.S. (6). If used, the inhalational solution should be filtered
using a 0.22-m filter to assure product sterility (7); however, U.S.
products are not currently tested for pyrogens or bacterial endo-
toxins, which would not be removed using this process (personal
communication, Bristol-Myers Squibb Company, and American
Regent Laboratories, July 2003).
Dribben et al. (7) recently reported the stability of inhalational
NAC when compounded in 5% dextrose (D5W). Stability data
using inhalational NAC in solutions other than D5W are limited,
although RAPPID investigators used saline. The rate and volume
of normal saline used as the diluent in this study may have
contributed to their positive findings. Clinicians using IV NAC
must proactively determine whether the most widely accepted
diluent in the U.S. should be used, and whether adjunctive saline
hydration has the potential to increase the incidence of adverse
outcomes observed in the RAPPID trial if D5W is chosen as a
diluent.
Until data establishing the appropriate dose and safety of
inhalational NAC administered IV are available, we recommend
administration of saline hydration in conjunction with immediate
initiation of oral NAC 600 mg twice daily for four doses in patients
undergoing emergent procedures. This regimen appears to be safe,
inexpensive, and effective for minimizing the risk of RCIN.
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REPLY
We understand that intravenous (IV) n-acetylcysteine (NAC) as
used in our study (Celltech Pharmaceuticals, Berkshire, SL1 3WE,
United Kingdom) is not available in the U.S. We agree with
Huxtable and colleagues’ concerns over the use of inhalational
NAC for the prevention of radiocontrast-induced nephropathy
(RCIN), particularly as this preparation requires the use of 5%
dextrose as the diluent. Although a saline-induced diuresis appears
to be effective in reducing the incidence of RCIN (1) there is no
evidence for the efficacy or otherwise of 5% dextrose.
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In the absence of a proven IV preparation, the proposal by
Huxtable et al. for the use of saline hydration and oral NAC seems
eminently sensible although, as they point out, evidence for the
effectiveness of oral NAC when given immediately prior to
contrast exposure is limited. A variety of other maneuvers may also
reduce the incidence of RCIN, and we would suggest the following
be included in any protocol:
1. The use of iso-osmolar contrast agents (2).
2. Minimization of the radiocontrast dose employed (3) (e.g.,
biplane imaging and echocardiography in place of contrast
ventriculography).
3. Maximum 4-h fast prior to contrast exposure to prevent salt and
water depletion.
4. Cessation of potentially nephrotoxic drugs prior to contrast
exposure and reinstitution when renal function has been shown
to be stable.
5. Assessment of renal function three days’ postprocedure.
We believe that awareness of RCIN will do much to reduce its
impact.
The suggestion of a third arm to the study to compare oral and
IV NAC is an interesting one. However, this was discounted
during the design stage of our trial owing to the low incidence of
RCIN in patients treated with oral NAC (approximately 2% [4]).
The estimated number of patients required to show a difference or
to prove equivalence between treatments would thus have been
prohibitively large.
Finally, we emphasize that our study did not include emergency
patients, as this would not have allowed randomization to the
slower hydration arm of the protocol.
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NAD(P)H Oxidase in
the Failing Human Heart
With great interest we read the recent JACC editorial comment by
Warnholtz and Munzel (1) in which they emphasize the impor-
tance of NAD(P)H-derived reactive oxygen species in heart
failure. This comment was for the greater part inspired by the
interesting study by Heymes et al. (2) published in the same issue
of JACC, which shows by immunohistochemistry that gp91phox is
expressed in human cardiomyocytes.
In their editorial comment, Warnholtz and Munzel state that
Heymes et al. (2) for the first time provide evidence of the activation
and expression of the NAD(P)H oxidase in human cardiomyocytes.
However, in March 2003 we already published a study in which we
provided evidence for the expression of gp91phox (Nox2) in human
cardiomyocytes (3). This was proven not only by immunohistochem-
istry but also by Western blot analysis on isolated human cardiomyo-
cytes instead of total-tissue homogenates.
Although both studies describe the expression of Nox2 in
human cardiomyocytes, there are some differences. For example,
Heymes et al. (2) show by Western blot on total-tissue homoge-
nates that there is no difference in Nox2 expression between failing
and nonfailing hearts, whereas we demonstrated by immunohisto-
chemistry that the number of Nox2-expressing cardiomyocytes within
the infarction area is significantly increased after acute myocardial
infarction (AMI). We have to keep in mind, however, that with AMI
we have studied an acute phenomenon, whereas congestive heart
failure (CHF) is a more or less chronic process. This might explain the
interesting differences in the pattern of Nox2 expression between
acute and chronic heart disease and could point to a different
regulation of Nox2 expression in both phenomena.
The data of Heymes et al. (2) therefore, corroborate our own
findings in that we both, using different antibodies, show that
Nox2 is expressed in human cardiomyocytes. Their measured
increase in NAD(P)H oxidase activity after CHF and our in-
creased Nox2 expression after AMI emphasize the role of the
NAD(P)H oxidase(s) in human cardiovascular pathophysiology.
We completely agree with Warnholtz and Munzel that the
possible co-expression of other Nox isoforms, the functional
contribution of the cardiomyocyte-specific oxidases to the ROS-
mediated effects observed in cardiac tissue homogenates, and the
search for possibilities of pharmacological intervention are impor-
tant issues that need to be addressed now.
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